Eli Lilly reaps rewards of Novo acquisition

By acquiring Dicerna, Novo Nordisk has sent DKK 700m (USD 107m) into the hands of its competitor Eli Lilly in the form of returns on shares in the acquired company, which Lilly co-owns.

Photo: Novo Nordisk / PR

On Thursday, Novo Nordisk annouced that it is acquiring the US-based biotech company Dicerna for USD 3.3bn.

The Dicerna acquisition has sent a big check to diabetes competitor Eli Lilly, which has several development partnerships with Dicerna.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs